Skip to main content

Peer Review reports

From: Cannabidiol (Epidyolex®) for severe behavioral manifestations in patients with tuberous sclerosis complex, mucopolysaccharidosis type III and fragile X syndrome: protocol for a series of randomized, placebo-controlled N-of-1 trials

Original Submission
27 Jul 2023 Submitted Original manuscript
31 Aug 2023 Reviewed Reviewer Report - Walter E. Kaufmann
7 Sep 2023 Reviewed Reviewer Report
7 Sep 2023 Reviewed Reviewer Report
3 Oct 2023 Author responded Author comments - Agnies M van Eeghen
26 Oct 2023 Reviewed Reviewer Report
1 Nov 2023 Reviewed Reviewer Report - Walter E. Kaufmann
23 Nov 2023 Author responded Author comments - Agnies M van Eeghen
Resubmission - Version 2
3 Oct 2023 Submitted Manuscript version 2
25 Nov 2023 Author responded Author comments - Agnies M van Eeghen
Resubmission - Version 3
25 Nov 2023 Submitted Manuscript version 3
28 Nov 2023 Author responded Author comments - Agnies M van Eeghen
Resubmission - Version 4
28 Nov 2023 Submitted Manuscript version 4
Publishing
29 Nov 2023 Editorially accepted
4 Jan 2024 Article published 10.1186/s12888-023-05422-3

You can find further information about peer review here.

Back to article page